Carl Zeiss Meditec has strong fundamentals and growth potential. It has impressive free cash flow and rising shareholder ...

There's been a notable change in appetite for Carl Zeiss Meditec AG shares in the week since its yearly report, with the stock down 15% to €49.30. Revenues were €2.1b, approxi ...

ZEISS and Mindpeak partner to advance Multiplex Immunofluorescence (mIF) solutions for pathology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Earlier this year, ZEISS established a Sales and Service Company in Canada for its Industrial Quality Solutions portfolio to strengthen customer excellence throughout the region. "For more than ...

Narrow-moat Carl Zeiss Meditec reported soft fourth-quarter earnings that came in lower than our expectations and ended the year on a soft note. Total sales of EUR 580 million during the quarter ...

ZEISS and the HÜBNER Group have unveiled an innovative holographic display technology for public transit, integrating ...

UBS analyst Graham Doyle maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report) today and set a price target of €65.00. The ...

ZEISS Research Microscopy Solutions and AI pathology leader Mindpeak have joined forces to develop an integrated Multiplex ...

ZEISS India, a technology expert in optics and optoelectronics, has inaugurated its first ZEISS VISION CENTRE in the city in association with Image Optical Company, a top official said on Tuesday. The ...

RBC Capital analyst Jack Reynolds-Clark maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report) today and set a price target of €70.00. The company’s shares closed yesterday at €58.93.